Responses
Late-breaking abstracts
Clinical trials in-progress
803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.